Fondaparinux in acute coronary syndromes Fondaparinux Chaturvedi & Karthikeyan

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 12, 2009, Pages 1615-1623

  Chaturvedi, Vivek ^a   Karthikeyan, Ganesan ^b  

^a G B PANT HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute coronary syndrome; Antithrombotics; Bleeding; Factor Xa; Fondaparinux; Heparin

Indexed keywords

ALTEPLASE; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; STREPTOKINASE; THROMBIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; CATHETER THROMBOSIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ISCHEMIA; MAXIMUM PLASMA CONCENTRATION; PERCUTANEOUS CORONARY INTERVENTION; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; FIBRINOLYTIC AGENTS; HUMANS; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 71149100511     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903456039     Document Type: Review

References (33)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442
2. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355(9219):1936-1942
3. Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005;112(25):3855-3867
4. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the spectrum of acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007;28(17):2077-2086
5. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-782
6. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005;96:1200-1206
7. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents -the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002;20(1):37-52
8. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003;109:1-11
9. Lormeau JC, Hérault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic AT-III-binding pentasaccharide. Thromb Haemost 1993;69:152-156
10. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:2653-2655
11. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995;74:1468-1473
12. Donat F, Duret JP, Santoni A. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002;41(Suppl 2):1-9 (Pubitemid 35155551)
13. Simoons ML, Bobbink IW, Boland J, et al.; PENTUA Investigators. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004;43(12):2183-2190
14. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa-inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001;22:1716-1724
15. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476
16. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-1530
17. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-1823
18. Peters RJG, Joyner C, Bassand JP, et al.; for the OASIS-6 Investigators. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur heart J 2008;29:324-331
19. Mehta SR, Boden WE, Eikelboom JW, et al.; for the OASIS 5 and 6 Investigators. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes. An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials. Circulation 2008;118:2038-2046
20. Budaj A, Eikelboom JW, Mehta S, et al.; on behalf of OASIS-5 Investigators. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009;30:655-661
21. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007;116(5):552-560
22. Turpie AGG, Bauer KA, Eriksson BI, et al.; for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Ann Intern Med 2002;162:1833-1840
23. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Inter-ventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304
24. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-1660
25. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909-2945
26. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-2885
27. Mega JL, Braunwald E, Mohanavelu S, et al.; on behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38
28. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374:787-879
29. Stome GW, Mclaurin BT, Cox DA, et al.; for the ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216
30. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: a meta-analysis based on individual patient data. Lancet 2002;359:294-302
31. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358(9296):1855-2633
32. Stone GW, Witzenbichler B, Guagliumi G, et al.; for the HORIZONS-AMI Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230
33. Zeymer U, Gitt A, Zahn R, et al. Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. EuroIntervention 2009;4(4):524-528